During an R&D update yesterday Merck said it is hoping to claim eight new cardiovascular therapy approvals between now and 2030, for diseases like atherosclerosis, heart failure, pulmonary ...

Merck & Co has said building its cardiovascular medicines business is central to its strategy to manage the loss of patent protection of cancer juggernaut Keytruda in five years, and new studies ...

For analyzing alterations in membrane potential, control and AA-treated bacteria were resuspended in 1 ml of PBS containing 30 μM of the potentiometric dye DiOC2(3) (BacLight Membrane Potential Kit, ...